Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Shares of Ekso Bionics Holdings (EKSO) traded up $0.48 during midday trading on Monday, reaching $1.53. 7,538,300 shares of the company’s stock traded hands, compared to its average volume of 528,927. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18. Ekso Bionics Holdings has a 1 year low of $0.99 and a 1 year high of $4.90.

Ekso Bionics Holdings (NASDAQ:EKSO) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%. research analysts expect that Ekso Bionics Holdings will post -0.81 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/13/ekso-bionics-holdings-inc-ekso-cut-to-sell-at-zacks-investment-research.html.

In related news, insider Russ Angold sold 28,254 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $1.53, for a total transaction of $43,228.62. Following the transaction, the insider now directly owns 250,678 shares of the company’s stock, valued at $383,537.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders acquired 41,264 shares of company stock worth $48,255 and sold 259,352 shares worth $399,373. 7.10% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in EKSO. Vanguard Group Inc. lifted its position in shares of Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after purchasing an additional 176,197 shares in the last quarter. National Planning Corp lifted its position in shares of Ekso Bionics Holdings by 116.2% during the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after purchasing an additional 126,000 shares in the last quarter. Carl Domino Inc lifted its position in shares of Ekso Bionics Holdings by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after purchasing an additional 102,734 shares in the last quarter. Finally, Intellectus Partners LLC lifted its position in shares of Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after purchasing an additional 5,294 shares in the last quarter. 2.85% of the stock is currently owned by institutional investors.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.